Immunitybio, Inc.
Clinical trials sponsored by Immunitybio, Inc., explained in plain language.
-
New hope for bladder cancer patients unable to join trials
Disease control AVAILABLEThis program provides a genetically modified version of the standard BCG treatment to people with non-muscle invasive bladder cancer who are not able to join a clinical trial. It is for adults aged 18 and older with high-grade transitional cell carcinoma. The goal is to offer a p…
Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 28, 2026 23:21 UTC
-
New hope for aggressive brain cancer: combo therapy trial launches
Disease control Recruiting nowThis study tests a combination of drugs (nogapendekin alfa inbakicept, bevacizumab, and immune cells called PD-L1 t-haNK) with or without tumor treatment fields (a device that uses electric fields to disrupt cancer growth) in people whose glioblastoma has come back or worsened. T…
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 28, 2026 23:20 UTC
-
Could anktiva ease long COVID? small trial launches
Symptom relief Recruiting nowThis study tests whether a drug called Anktiva is safe and tolerable for people with Long COVID. About 20 adults who have had COVID-19 will receive up to two doses and be monitored for side effects and symptom changes. The goal is to see if this treatment can help reduce ongoing …
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Symptom relief
Last updated Apr 26, 2026 20:00 UTC